A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naive Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)

Trial Profile

A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naive Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Radium 223 chloride (Primary) ; Abiraterone acetate; Prednisolone; Prednisone
  • Indications Adenocarcinoma; Bone metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ERA223
  • Sponsors Bayer
  • Most Recent Events

    • 30 Nov 2017 According to a company media release, Bayer is unblinding this trial per the recommendation of an Independent Data Monitoring Committee (IDMC). The IDMC recommendation is due to the observation of an imbalance of more fractures and deaths in the treatment arm of this trial.
    • 30 Nov 2017 According to a Bayer media release, an Independent Data Monitoring Committee (IDMC) has recommended to unblind this trial due to the observation of an imbalance of more fractures and deaths in the treatment arm.
    • 06 Sep 2017 Planned primary completion date changed from 15 Dec 2017 to 15 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top